-
As you review which talking points to cover with your next patient, are you planning to include dialogue on the link between human papillomavirus (HPV) and cervical cancer?
-
-
Teens may be up to speed when it comes to movies, music, and sports, but when it comes to knowledge of prevention and treatment of sexually transmitted diseases (STDs), they are falling behind, a new national report reveals.
-
Ready to update your knowledge on family planning issues and network with fellow clinicians? Take advantage of upcoming fall conferences, all aimed at family planning providers.
-
Rewind to 1998: The Centers for Disease Control and Prevention (CDC) launches its plan to eliminate syphilis in the United States, with the goals of reducing the total number of primary and secondary syphilis cases to 1,000 or fewer 0.4 cases per 100,000 people and increasing the number of syphilis-free counties to 90% by 2005.
-
Reaching teens with up-to-date information is an important part of providing family planning and sexually transmitted disease (STD) counseling. Consider these web sites:
-
Is use of depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) linked to risk of toxic shock syndrome? Contraceptive Technology Update Editorial Advisory Board member Felicia Stewart, MD, adjunct professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California San Francisco and co-director of the Center for Reproductive Health Research & Policy, tackles this question.
-
New data from a long-term cohort study comparing bone mineral densities (BMD) in adult users and nonusers of the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) indicate that while bone mineral density declines in current DMPA users, it is followed by substantial recovery after discontinuation.
-
The company responsible for developing the Essure non-incisional permanent birth control procedure is seeking approval from the Food and Drug Administration (FDA) to extend effectiveness data on the Essure product labeling.
-
By Malcolm Robinson, MD, FACP, FACG
Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK
Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca, and Centocor.